En­livex halts on­col­o­gy re­search, lays off 50% of staff; Mod­er­na warns against TRC Cap­i­tal mi­ni-ten­der

En­livex Ther­a­peu­tics is stop­ping all clin­i­cal de­vel­op­ment of its on­col­o­gy drug can­di­dates as well as lay­ing off 50% of its work­force. The com­pa­ny plans to seek ex­ter­nal col­lab­o­ra­tions and out-li­cens­ing op­por­tu­ni­ties for its on­col­o­gy as­sets.

As of Dec. 2022, the Ness Ziona, Is­rael-based com­pa­ny had 77 em­ploy­ees. The com­pa­ny is re­fo­cus­ing its at­ten­tion in­to in­flam­ma­to­ry and au­toim­mune ther­a­pies, as per its sec­ond quar­ter re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER